EGFR and non-small cell lung carcinoma: A single-center retrospective study that included 184 EGFR/ALK-driven NSCLC patients with BMs found no independent effect due to first-line CNS treatment choice (WBRT, SRS or TKI) in EGFR/ALK-driven NSCLC, but the choice of first-line WBRT for BMs from EGFR/ALK-driven NSCLC was associated with a longer time to intracranial progression than SRS or TKI alone [21].